Andra AP fonden Acquires 290,412 Shares of Astrazeneca Plc $AZN

Andra AP fonden boosted its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 122.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 526,714 shares of the company’s stock after buying an additional 290,412 shares during the period. Astrazeneca makes up about 1.1% of Andra AP fonden’s portfolio, making the stock its 15th largest position. Andra AP fonden’s holdings in Astrazeneca were worth $99,876,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Kestra Investment Management LLC increased its position in shares of Astrazeneca by 1.9% during the fourth quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock worth $595,000 after acquiring an additional 63 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its stake in Astrazeneca by 51.8% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 258 shares of the company’s stock valued at $50,000 after purchasing an additional 88 shares during the last quarter. PFG Private Wealth Management LLC increased its holdings in Astrazeneca by 5.5% during the 2nd quarter. PFG Private Wealth Management LLC now owns 1,770 shares of the company’s stock worth $336,000 after purchasing an additional 92 shares in the last quarter. Spinnaker Investment Group LLC raised its stake in shares of Astrazeneca by 3.8% in the second quarter. Spinnaker Investment Group LLC now owns 2,899 shares of the company’s stock worth $550,000 after purchasing an additional 106 shares during the last quarter. Finally, Syon Capital LLC lifted its holdings in shares of Astrazeneca by 0.9% in the second quarter. Syon Capital LLC now owns 12,068 shares of the company’s stock valued at $2,288,000 after purchasing an additional 110 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

Key Stories Impacting Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Enhertu gains important reimbursement support in England. The NHS cleared AstraZeneca and Daiichi Sankyo’s Enhertu for patients with HER2-low metastatic breast cancer, reversing an earlier cost-effectiveness-related rejection. Expanded NHS access could increase the drug’s eligible patient population and strengthen its commercial outlook. AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England
• Positive Sentiment: European regulatory momentum broadens AstraZeneca’s pipeline. The European Medicines Agency’s CHMP issued positive opinions for Enhertu and Klygefa. Klygefa was recommended for AChR-positive generalized myasthenia gravis based on Phase III results and offers a once-weekly treatment option. CHMP opinions are not final approvals, but they generally support the products’ path to commercialization in Europe. AstraZeneca’s Enhertu, Klygefa Get Positive CHMP Opinions in EU
• Positive Sentiment: Efzimfotase alfa received FDA priority review. The designation for the hypophosphatasia treatment may accelerate the U.S. regulatory process and highlights another potential growth driver beyond AstraZeneca’s established oncology portfolio. FDA Grants Priority Review to AstraZeneca’s Efzimfotase Alfa
• Positive Sentiment: Erste Group Bank raised its earnings forecasts. The bank increased its FY2026 EPS estimate to $10.34 from $10.17 and its FY2027 estimate to $11.50 from $11.44. Both forecasts are above the cited full-year consensus estimate of $9.34, suggesting confidence in AstraZeneca’s earnings trajectory.
• Neutral Sentiment: Market-performance comparisons remain mixed. Recent coverage noted that AZN shares advanced but continued to lag the broader market, keeping valuation, execution, patent exposure and pipeline delivery as important investor concerns. AstraZeneca Ascends But Remains Behind Market

Astrazeneca Stock Performance

Shares of AZN traded up $0.33 on Tuesday, reaching $168.43. 1,060,194 shares of the company’s stock traded hands, compared to its average volume of 2,806,251. The stock’s 50 day simple moving average is $164.03 and its two-hundred day simple moving average is $180.13. The stock has a market cap of $261.22 billion, a PE ratio of 25.19, a PEG ratio of 1.41 and a beta of 0.25. Astrazeneca Plc has a 52-week low of $145.79 and a 52-week high of $212.71. The company has a current ratio of 0.89, a quick ratio of 0.67 and a debt-to-equity ratio of 0.47.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings data on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.13. The business had revenue of $15.38 billion for the quarter, compared to analysts’ expectations of $15.44 billion. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The business’s revenue was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.17 earnings per share. On average, analysts forecast that Astrazeneca Plc will post 9.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on AZN shares. Bank of America reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Wall Street Zen cut Astrazeneca from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Zacks Research downgraded shares of Astrazeneca from a “hold” rating to a “strong sell” rating in a report on Monday, September 14th. Finally, Royal Bank Of Canada began coverage on shares of Astrazeneca in a research report on Tuesday, September 8th. They set an “outperform” rating on the stock. Fourteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $206.67.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines. Its principal therapeutic areas include oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology conditions, and rare diseases.

The company’s portfolio includes medicines such as Tagrisso, Imfinzi and Lynparza for cancer; Farxiga for cardiovascular, kidney and metabolic conditions; Fasenra for severe asthma; and Symbicort for respiratory disease.